Mayo Clinic laboratory and pathology research roundup: November 16
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
Although grading systems have been proposed for chromophobe renal cell carcinoma (ChRCC), including a three-tiered system by Paner et al (Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol 2010;34:1233-40), none have gained clinical acceptance, and the World Health Organization (WHO) currently recommends against grading ChRCC. Via European Urology
Published to PubMed This Week
- Anti-Mullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.
Journal of the National Cancer Institution - Protein Contributions to Brain Atrophy Acceleration in Alzheimer's Disease and Primary Age-Related Tauopathy.
Brain - Education and Outreach in Physical Sciences in Oncology.
Trends in Cancer - Somatic Copy Number Gains in MYC, BCL2, and BCL6 Identifies a Subset of Aggressive Alternative-DH/TH DLBCL Patients.
Blood Cancer Journal - Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors.
Mayo Clinic Proceedings - Impact of the SARS-CoV-2 Pandemic on Emergency Department Presentations in an Integrated Health System.
Mayo Clinic Proceedings - Fibroadenoma of the Breast.
Mayo Clinic Proceedings - Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic.
Mayo Clinic Proceedings - Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
American Journal of Surgical Pathology - Bone Marrow Dendritic Cell Aggregates Associate with Systemic Immune Dysregulation in Chronic Myelomonocytic Leukemia.
Blood Advances
